Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab-Reference-Cited by-同舟云学术

Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab

Published:2016-02 Issue:1 Volume:6 Page:5-12
ISSN:1758-2024
Container-title:Neurodegenerative Disease Management
language:en
Short-container-title:Neurodegenerative Disease Management

Author:

Arpín Eva Costa¹,Sobrino Tania García¹,Vivero Clara Domínguez¹,del Campo Amigo Jorrín María²,Regal Ana Rodríguez²,González José Prieto¹,Bouzas Manuela Lema¹

Affiliation:

1. Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain

2. Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain

Abstract

Aim: To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy. Patients and methods: We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1–4 years. Results: In the study population (n = 29), baseline mean CCI was 0.37 ± 0.04 and final CCI 0.36 ± 0.04. 17 patients did not develop brain atrophy during follow-up. There was no statistically significant relationship between progression of atrophy and clinical and radiological parameters. Conclusion: Natalizumab may have a neuroprotective effect.

Publisher

Future Medicine Ltd

Subject

Neurology (clinical)

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nmt.15.53

Reference39 articles.

1. Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

2. Multiple Sclerosis

3. Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies

4. The clinico-radiological paradox in multiple sclerosis revisited

5. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data;Multiple Sclerosis and Related Disorders;2024-07

2. The association between brain volume loss and disability in multiple sclerosis: A systematic review;Multiple Sclerosis and Related Disorders;2023-06

3. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates;Brain and Behavior;2022-04-10

4. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options;Autoimmunity Highlights;2019-08-10

5. Introducing a new volume of Neurodegenerative Disease Management;Neurodegenerative Disease Management;2017-02